Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059718 | 0.89 | GAA (0.48) | P2RX3P2RX2GAAMGAMSI | |
| SCHEMBL21142303 | 0.89 | GAA (0.48) | P2RX3P2RX2GAAMGAMSI | |
| SCHEMBL12190518 | 0.89 | P2RX3 (0.48) | P2RX3P2RX2GAAMGAMSI | |
| SCHEMBL13085628 | 0.89 | P2RX3 (0.43) | P2RX3P2RX2GAAMAPTHTR2A | |
| SCHEMBL9957945 | 0.86 | P2RX3 (0.38) | P2RX3P2RX2GAAMGAMSI | |
| SCHEMBL15927601 | 0.86 | P2RX3 (0.41) | P2RX3P2RX2GAAMGAMSI | |
| SCHEMBL29786811 | 0.86 | P2RX3 (0.38) | P2RX3P2RX2GAAMGAMSI | |
| SCHEMBL171073 | 0.85 | POLB (0.46) | P2RX3P2RX2GAAPOLBGFER | |
| SCHEMBL24449860 | 0.84 | ALOX15 (0.40) | P2RX3P2RX2GAAPOLBGFER | |
| SCHEMBL10085674 | 0.84 | P2RX3 (0.38) | P2RX3P2RX2GAAPOLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104557757-A | CETP inhibitors | MERCK & CO INC | 2015-04-29 | — | — | CN | disclosed |
| CN-104447603-A | CETP inhibitors | MERCK SHARP & DOHME | 2015-03-25 | — | — | CN | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7807690-B2 | 2,3-dihydro-iminoisoindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807690-B2 | 2,3-dihydro-iminoisoindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | SERPINC1, F7, F2 | P2RX3 4662/4885P2RX2 4613/4885GAA 2310/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | P2RX3 3232/4885P2RX2 3589/4885GAA 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.